Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure … (NCT07697833) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
500 participantsStarted 2026-07-15
Plain-language summary
To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age \>18 years of any gender
. Chronic heart failure (New York Heart Association \[NYHA\] functional class II, III, or IV), a reduced left ventricular ejection fraction of less than 45% within 12 months before randomization
. Elevated natriuretic peptide level: (For patients in sinus rhythm, the criteria include a plasma B-type natriuretic peptide (BNP) level of at least 300 pg per milliliter or an NT-proBNP level of at least 1000 pg per milliliter. For patients in atrial fibrillation, the criteria included a BNP level of at least 500 pg per milliliter or an NT-proBNP level of at least 1600 pg per milliliter).
. Evidence of worsening heart failure.
. The percentage of enrolled patients with an estimated glomerular filtration rate of 15 to 30 ml per minute per 1.73 m2 of body-surface area was capped at 15%.
. Patients on guideline-based medical therapy 3 months
. Written and informed consent.
Exclusion criteria
. Systolic blood pressure of less than 100 mm Hg.
. Concurrent or anticipated use of long-acting nitrates.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing vericiguat against standard medical treatment for heart failure with reduced ejection fraction — how does vericiguat compare to the medications I'm already on or might be offered, and would standard treatment be a reasonable first step for me before considering a trial like this?
2Since this trial is Phase 4, which means vericiguat has already been approved, what do we know so far about its safety and effectiveness in people with my type of heart failure, and are there any risks I should weigh carefully given my specific situation?
3The trial is measuring quality of life using something called the KCCQ-12 questionnaire — what does that mean in practical terms, and do you think improving day-to-day quality of life is the right goal to focus on for where I am right now?
4The trial isn't recruiting yet — given that timeline uncertainty, is it worth waiting to see if I might be eligible, or would it make more sense to start a treatment plan now so I'm not delaying care?
5What would my commitment look like if I were to eventually discuss enrolling — how often would I need to come in for visits, and are there aspects of the trial's demands that you think might be difficult to manage alongside my current health and daily life?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Quality of life using Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
Timeframe: Baseline to Month 6
Trial details
NCT IDNCT07697833
SponsorNational Institute of Cardiovascular Diseases, Pakistan